ERBB2 and triple-negative breast carcinoma: It is a new therapeutic target for triple-negative breast cancer, which is transcriptionally regulated by estrogen receptor-alpha, human epidermal growth factor receptor 2, and the progesterone receptor (Zhao et al., 2019).